ClinicalTrials.gg
CompletedNCT01760109PIP-SBTUpdated Jul 8, 2019

Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection

A Phase 4 interventional study of Piperacillin Sodium and Sulbactam Sodium in Respiratory Tract Infections and Urinary Tract Infections, sponsored by Xiangbei Welman Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Xiangbei Welman Pharmaceutical Co., Ltd · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Respiratory Tract Infections with a site in China — 13 open to participants now, 15 under way, 3 of them phase 3. Respiratory Tract Infections · China.

Enrollment
7th of 30
2,000 · median 202
Started
2011
with 2 others
Phase 4
5 of 40
none open now
Registered
8th of 40
by date
Lead sponsor
2 of 40
Xiangbei Welman Pharmaceutical Co., Ltd

Among the 40 studies in Respiratory Tract Infections with a site in China, this one is the 7th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2011, is one of 5 in phase 4, and was the 8th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

13 of the 40 studies in Respiratory Tract Infections with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Tract Infections with a site in China, or all of them as a file.
02

Study summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.

Read the detailed description

Piperacillin sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis,the latter making irreversible competitive inhibition of β-lactamase.The antimicrobial effect of Piperacillin can be enhanced by the two combined. The compound specifically aims to the mechanism of bacterial resistance, extending the life of Piperacillin in the treatment-resistant pathogen infections.

03

Conditions studied

  • Respiratory Tract Infections
  • Urinary Tract Infections

Keywords

  • Respiratory and urinary tract infections
  • Piperacillin Sodium and Sulbactam Sodium for Injection (2:1)
  • Phase IV
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients who qualify for moderate and severe acute respiratory or urinary tract bacterial infection of acute bacterial infections need for systemic antibiotic therapy.
  2. Age>18 years old, Gender: both
  3. Women of childbearing age were to be negative pregnancy test and agree to take measures during the trial;
  4. patients were volunteers and signed form;
  5. patients did not participate in other clinical trials.

Exclusion criteria

Exclusion Criteria:

  1. Patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase inhibitor
  2. Pregnant and Lactating women
  3. Patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer or mental illness.
  4. Patients who were complicated by other diseases and thought to affect efficacy evaluations or poor compliance.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,000 participants (actual)

Study arms

  • Experimental
    Piperacillin Sodium and Sulbactam Sodium

    Drug:xintemie 1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days

    Drug: Piperacillin Sodium and Sulbactam Sodium

Interventions

  • DrugPiperacillin Sodium and Sulbactam Sodium

    Drug pages: Piperacillin · Sulbactam

    1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days

    Also known as: xin te mie, te mie jun, xin ke jun

06

What researchers measure

Primary outcomes

  1. The rate of bacterial clearance

    end of treatment of bacteriological efficacy(bactercial clearance) The fore-and-aft changes of clinical symptoms and signs after discontinuation of durgs

    Time frame: two years

Secondary outcomes

  1. Number of participants with Adverse Events

    the incidence(%)of allergies, skin rashes, shock,death, etc.

    Time frame: two years

07

Study locations

1 site
  • Chongqing Red Cross hospital
    Chongqing, 400020, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2012
First posted
Jan 3, 2013
Start
Jul 2011
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01760109
Lead sponsor
Xiangbei Welman Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Jan 3, 2013
Start date
Jul 2011
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jul 8, 2019

Study contacts

Changqing Li, doctor
principal investigator · Chongqing Red Cross Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Piperacillin · Sulbactam

Start the discussion